Outset Medical, a leading medical technology company transforming the dialysis landscape, announced new research findings from over one million Tablo hemodialysis treatments across approximately 750 facilities, alongside five-year clinical and operational results from a major hospital in Florida. The data will be presented during the American Society of Nephrology’s Kidney Week 2025, taking place November 5–8 in Houston.
The annual conference brings together more than 12,000 kidney care professionals from around the world to showcase the latest advances in nephrology.
A highlight of the presentations comes from AdventHealth, which implemented in-sourced dialysis services using the Tablo Hemodialysis System at its Ocala, Florida, facility. Over five years, the site recorded a 94 per cent reduction in serious cardiac or respiratory events, a sustained decline in central-line bloodstream infections, and a nurse retention rate exceeding 95 per cent. The transition also yielded a strong return on investment within two years of operation, underscoring the economic and clinical value of insourcing dialysis with Tablo.
Broader data from over one million Tablo treatments performed across more than 600 facilities reinforced the technology’s clinical effectiveness and operational reliability. Among 10,000 treatments lasting between 23 and 24 hours—typically for the most critical patients—facilities achieved over 99% treatment completion with minimal interruptions and rapid alarm resolution.
“We believe these findings provide additional support for an insourced dialysis service line to elevate the standard of care at hospitals serving patients with compromised renal function,” said Dr Michael Aragon, Chief Medical Officer at Outset Medical. “Outset’s growing base of clinical, financial, and operational evidence demonstrates that the advantages of insourcing for acute-care facilities can range from hard clinical benefits to significant cost savings and improved patient outcomes.”
Outset Medical’s Tablo Hemodialysis System is designed to reduce the cost and complexity of dialysis by integrating water purification, on-demand dialysate production, and digital connectivity into a single, easy-to-use device. The company’s ongoing research continues to demonstrate how insourcing dialysis can help hospitals improve efficiency, enhance patient safety, and expand access to high-quality renal care.
